Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD

(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and...

Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Saturday 7 November →